Martin Hegen | Human Dose Predictions | Best Researcher Award

Published on by Research Data Analysis

Dr. Martin Hegen | Human Dose Predictions | Best Researcher Award

Pfizer | United States

PUBLICATION PROFILE

Scopus

🧑‍🔬 INTRODUCTION

Dr. Martin Hegen is a highly accomplished Research Fellow at Pfizer, widely respected for his leadership and scientific expertise in immunology and inflammation. With more than 20 years of experience in the pharmaceutical industry, Dr. Hegen has made substantial contributions to drug discovery and development, driving projects from portfolio entry to clinical proof-of-concept. His work bridges rigorous scientific research with strategic leadership, ensuring high-quality results and consistent compliance with regulatory and ethical standards.

🎓 EARLY ACADEMIC PURSUITS

Dr. Hegen began his academic journey in Germany, earning a Ph.D. in Immunology magna cum laude from Johannes Gutenberg-University of Mainz in 1993, after receiving an M.Sc. in Biology in 1988. He then undertook a postdoctoral fellowship at the Dana-Farber Cancer Institute, Harvard Medical School, where he explored critical signaling mechanisms in T cell activation involving CD26 and CD45 isoforms. This foundational research into immune system regulation shaped his scientific perspective and laid the groundwork for a successful career in translational immunology.

🧪 PROFESSIONAL ENDEAVORS

Dr. Hegen’s professional career spans over two decades of increasing responsibility and impact. He joined Wyeth Research in 2001, focusing on inflammatory diseases and advancing several therapeutic antibody programs. Following Pfizer’s acquisition of Wyeth in 2009, Dr. Hegen transitioned into the Inflammation & Immunology Research Unit at Pfizer, where he held several key roles including Senior Principal Scientist, Associate Research Fellow, and currently, Research Fellow. Throughout these positions, he provided scientific and managerial leadership for autoimmune disease models, led project teams, and mentored research scientists, including Ph.D.-level staff. He has directed collaborative programs across international sites and partnered with academic and biotech institutions to accelerate therapeutic innovation.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS

Dr. Hegen’s scientific contributions are focused on autoimmune and inflammatory diseases, such as rheumatoid arthritis, lupus, psoriasis, inflammatory bowel disease, and multiple sclerosis. His expertise includes the use of gene-deficient mice and other advanced preclinical models to validate therapeutic targets. He has led efforts in both biologic and small molecule programs, guiding lead molecule selection and supporting successful clinical trials. His deep understanding of disease pathogenesis and experience with regulatory filings has been vital in bringing investigational drugs like Tofacitinib through the pipeline.

🌍 IMPACT AND INFLUENCE

Throughout his career, Dr. Hegen has left a lasting impact through both scientific contributions and leadership. Under his supervision, multiple scientists have received Individual Performance Awards. His strategic guidance and scientific rigor have influenced key decision-making processes, from target prioritization to portfolio entry and in-licensing evaluations. His work on clinical programs such as Ozoralizumab and other Janus kinase inhibitors has directly shaped Pfizer’s therapeutic portfolio in immunology.

📚 ACADEMIC CITATIONS AND PUBLICATIONS

Dr. Hegen has a strong publication record and has served on editorial boards for leading journals such as The Journal of Immunology, Inflammation Research, and Journal of Leukocyte Biology. He has contributed peer reviews and editorial oversight for decades, influencing scholarly standards in immunology and inflammation research. His expertise is frequently sought after in reviewing cutting-edge scientific findings, and he has held roles as associate editor and invited chairman at international immunology conferences.

🏆 HONORS & AWARDS

Dr. Hegen’s achievements have been recognized by prestigious organizations. He received a postdoctoral fellowship from the German Research Society and was honored with Wyeth’s “Above and Beyond Award” in 2003. He was selected for elite leadership training programs at Wyeth (Eagles Program) and Pfizer (Cornerstones of Management), highlighting his commitment not only to science but also to cultivating leadership excellence.

🧬 PATENTS

Dr. Hegen is listed as an inventor on multiple patents, emphasizing his role in therapeutic innovation. These include methods for using antibodies against IL-22, anti-M-CSF antibodies for treating inflammatory disorders, and the development of modified single-domain antibody molecules targeting TNF-α. His patents contribute to the intellectual property backbone supporting Pfizer’s clinical development programs.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Dr. Martin Hegen’s legacy is defined by scientific excellence, impactful leadership, and the successful advancement of multiple therapeutic programs. His work has significantly contributed to the understanding and treatment of complex autoimmune diseases. As an active member of the American College of Rheumatology and American Association of Immunologists, he continues to shape the future of immunology research. Dr. Hegen remains committed to mentoring the next generation of scientists and driving forward innovations that will improve patient care worldwide.

📝 FINAL NOTE

Dr. Martin Hegen represents the highest standard of professionalism, scientific insight, and collaborative leadership in biomedical research. His career reflects a rare combination of deep academic training, pharmaceutical innovation, and strategic execution. As immunology continues to evolve, Dr. Hegen’s enduring influence will be felt in both clinical outcomes and the growing body of scientific knowledge advancing human health.

 📚 TOP NOTES PUBLICATIONS

Cure as a treatment target in rheumatoid arthritis and systemic sclerosis—achievable aim or mission impossible? FOREUM stimulates new industry-academia collaboration

    • Authors: Kenneth F. Baker, J. Spierings, Martin Brom, Stephen Oliver, Richard Veselý

    • Journal: Rheumatology (exact journal not specified, likely from context)

    • Year: (Not explicitly provided, but likely 2023 or 2024)

RORγt inhibition ameliorates IL-23 driven experimental psoriatic arthritis by predominantly modulating γδ-T cells

    • Authors: Céline Mortier, Eric Gracey, Julie Coudenys, Dirk Elewaut, Koen J.T. Venken

    • Journal: Rheumatology

    • Year: 2023

A Novel C-C Chemoattractant Cytokine (Chemokine) Receptor 6 (CCR6) Antagonist (PF-07054894)…
(Truncated title: “…Distinguishes between Homologous Chemokine Receptors, Increases Basal Circulating CCR6⁺ T Cells, and Ameliorates Interleukin-23-Induced Skin Inflammation”)

    • Authors: Wei Li, Kimberly K. Crouse, Jennifer Alley, Michael S. Vincent, Gabriel Berstein

    • Journal: Journal of Pharmacology and Experimental Therapeutics

    • Year: 2023

Studies with neutralizing antibodies suggest CXCL8-mediated neutrophil activation is independent of C-C motif chemokine receptor-like 2 (CCRL2) ligand binding function

    • Authors: Zhenwei Su, Jonathan M. Brooks, Jeffrey W. Pelker, Alfredo Darmanin Sheehan, Joseph J. Brennan

    • Journal: PLoS ONE

    • Year: 2023

Suncheng Xiang | Machine Learning and AI Applications | Best Researcher Award

Published on by Research Data Analysis

Assist Prof Dr. Suncheng Xiang | Machine Learning and AI Applications | Best Researcher Award

Shanghai Jiao Tong University | China

PUBLICATION PROFILE

Google Scholar

🎓 EARLY ACADEMIC PURSUITS

Dr. Suncheng Xiang’s academic journey began with a B.S. in Electrical Engineering and Automation from Changsha University of Science & Technology (2010–2014), where he demonstrated early promise through multiple scholarships and honors. He pursued an M.S. in Software Engineering at the National University of Defense Technology (NUDT) from 2014 to 2017, continuing his academic excellence with multiple recognitions, including first-class scholarships and “Outstanding Student” awards. His scholarly momentum led to a Ph.D. in Computer Science and Technology at Shanghai Jiao Tong University (SJTU) from 2017 to 2022, where he laid the foundation for his work at the intersection of artificial intelligence and medical technology.

💼 PROFESSIONAL ENDEAVORS

Currently serving as an Assistant Professor at the School of Biomedical Engineering, SJTU, since August 2022, Dr. Xiang is also co-affiliated with the Institute of Medical Robotics, reflecting his interdisciplinary engagement. His teaching portfolio includes courses like Artificial Intelligence and Medicine and Medical Imaging Intelligence Technology, and he has served as a lead TA in core computing courses during his academic years. His professional memberships with IEEE and ACM further demonstrate his integration into the global scientific community.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS

Dr. Xiang’s research lies at the convergence of machine learning, computer vision, and biomedical applications, with significant work in domain adaptation, image generation, 3D reconstruction, and multimodal foundation models. He has contributed to both theoretical advancements and real-world solutions, evident in his published preprints on arXiv, which explore topics such as polyp re-identification, medical image segmentation, and gesture recognition. His innovation extends to patents—notably in vessel re-identification using transfer learning and a reusable implantable drive mechanism.

🌍 IMPACT AND INFLUENCE

As an active reviewer for more than 40 peer-reviewed journals—including prestigious outlets like IEEE Transactions on Medical Imaging, Pattern Recognition, and Machine Learning—Dr. Xiang holds a Distinguished Reviewer title. He is also an associate editor for several journals such as Biomedical Engineering Communications and Intelligent Manufacturing. His presence at major conferences like CVPR, ICCV, MICCAI, and EMNLP as a reviewer, session chair, or workshop organizer highlights his growing influence in global academic discourse. Additionally, his invited talks at leading institutions such as Fudan University, Wuhan University, and international platforms demonstrate his thought leadership.

📈 ACADEMIC CITES

Dr. Xiang’s open-source philosophy and dedication to knowledge sharing are reflected in his active GitHub repository, where he shares code and models related to his publications. This contributes to his growing academic citations and impact, as his works are used by fellow researchers and practitioners alike. Although specific citation metrics aren’t listed, his consistent involvement in high-profile research and collaboration across multidisciplinary teams suggests a rising citation trajectory.

🌟 LEGACY AND FUTURE CONTRIBUTIONS

Looking ahead, Dr. Xiang’s leadership in multimodal cognitive learning, AI for healthcare, and robotic surgery is poised to contribute significantly to next-generation biomedical systems. His ongoing national and municipal-level projects, including the National Natural Science Foundation of China Youth Project and Shanghai Municipal Health Commission projects, indicate sustained support and expectations from the research community. With a rich portfolio in teaching, mentorship, and interdisciplinary collaboration, Dr. Xiang is building a legacy that bridges technical innovation with clinical translation.

 📚 TOP NOTES PUBLICATIONS

Vm-unet: Vision mamba unet for medical image segmentation

    • Authors: J. Ruan, J. Li, S. Xiang

    • Journal/Conference: arXiv preprint arXiv:2402.02491

    • Year: 2024

Malunet: A multi-attention and light-weight unet for skin lesion segmentation

    • Authors: J. Ruan, S. Xiang, M. Xie, T. Liu, Y. Fu

    • Journal/Conference: 2022 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)

    • Year: 2022

Unsupervised domain adaptation through synthesis for person re-identification

    • Authors: S. Xiang, Y. Fu, G. You, T. Liu

    • Journal/Conference: 2020 IEEE International Conference on Multimedia and Expo (ICME)

    • Year: 2020

Less is more: Learning from synthetic data with fine-grained attributes for person re-identification

    • Authors: S. Xiang, D. Qian, M. Guan, B. Yan, T. Liu, Y. Fu, G. You

    • Journal/Conference: ACM Transactions on Multimedia Computing, Communications and Applications

    • Year: 2023

Learning from self-discrepancy via multiple co-teaching for cross-domain person re-identification

    • Authors: S. Xiang, Y. Fu, M. Guan, T. Liu

    • Journal/Conference: Machine Learning

    • Year: 2023

Rethinking illumination for person re-identification: A unified view

    • Authors: S. Xiang, G. You, L. Li, M. Guan, T. Liu, D. Qian, Y. Fu

    • Journal/Conference: Proceedings of the IEEE/CVF Conference on Computer Vision and Pattern Recognition (CVPR)

    • Year: 2022

Gilles-eric Seralini | Environmental Data Analysis | Lifetime achievement Award

Published on by Research Data Analysis

Prof. Gilles-eric Seralini | Environmental Data Analysis | Lifetime achievement Award

University Of Caen Normandy – Mrsh | France

PUBLICATION PROFILE

Google Scholar

📌 INTRODUCTION

Prof. Gilles-Éric Séralini, born on August 23, 1960 in Bône, Algeria (then under French rule), is a prominent French molecular biologist known for his pioneering work on genetically modified organisms (GMOs), endocrine disruptors, and environmental toxicology. Holding French nationality, he has built a distinguished academic and scientific career centered on public health, molecular biology, and scientific integrity. He is especially recognized for his commitment to independent research in the face of industrial and political pressures.

🎓 EARLY ACADEMIC PURSUITS

Séralini embarked on his academic journey in France, earning his Baccalauréat D in 1977 before progressing to higher studies in biology and biochemistry at Université de Nice and Université de Montpellier II. He obtained a DEA in Endocrinology and Development in 1983 as the major of his class, followed by a Ph.D. in Biochemistry and Molecular Biology in 1987, with a thesis focused on the effects of alpha-fetoprotein on reproductive health in rats. His postdoctoral studies took him to Canada, where he worked at the University of Western Ontario (1987–1989) and later at the CHU of Laval University in Quebec (1990–1991). He completed his Habilitation à Diriger des Recherches (HDR) in 1991 at the Université de Caen, marking the start of his supervisory and research leadership career.

👨‍🏫 PROFESSIONAL ENDEAVORS

Since October 1991, Prof. Séralini has served as a Professor of Molecular Biology at the Université de Caen, where he achieved the classe exceptionnelle, the highest academic title in French higher education. At Caen, he has led research in endocrinology, toxicology, and GMO risk assessment. He co-founded two major organizations: CRIIGEN (Committee for Independent Research and Information on Genetic Engineering) in 1999 and ENSSER (European Network of Scientists for Social and Environmental Responsibility), both advocating for unbiased scientific research and environmental responsibility. He has also supervised numerous Ph.D. theses, mentored young researchers, and secured major research grants.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS

Prof. Séralini’s research emphasizes the molecular and physiological impacts of environmental pollutants, especially GMOs and glyphosate-based herbicides. He has gained international recognition for conducting long-term toxicity studies on rats, demonstrating tumor development and organ damage due to prolonged glyphosate exposure—studies that sparked major debates worldwide. His work often critiques the methodologies used by regulatory agencies and calls for increased transparency and independence in science. Additionally, he has developed improved testing standards for chemical exposure and actively promotes public awareness through books and media.

🌍 IMPACT AND INFLUENCE

Séralini has significantly shaped global discussions around agrochemical safety, regulatory science, and science ethics. He has been consulted by the European Commission, EFSA, and various French ministries, and has provided expert testimony in several high-profile legal cases involving GMOs. His advocacy efforts have contributed to a broader awareness of environmental health risks and have called attention to the importance of scientific integrity in public policy. Despite facing strong opposition from industrial stakeholders, his work has inspired a global movement for ethical and independent research.

📚 ACADEMIC CITATIONS AND PUBLICATIONS

Over the decades, Prof. Séralini has authored more than 100 peer-reviewed articles, contributed to scientific books, and delivered numerous seminars and invited talks internationally. His research is frequently cited in the fields of molecular biology, toxicology, environmental health, and regulatory science. He also holds a patent and has participated in international and national conferences, further extending his academic impact.

🏆 HONORS & AWARDS

Prof. Séralini’s excellence and courage in scientific research have earned him numerous awards, including:

  • 🏅 Prix Philips (1998) for science communication

  • 🎖️ Ordre de l’Étoile de l’Europe (1999)

  • 🥇 Prix Denis Guichard (2001) from the Fondation de France

  • 🇫🇷 Chevalier de l’Ordre National du Mérite (2008)

  • 🛡️ International Whistleblower Award (2015, Germany)

  • 🌱 Théo Colborn Award (2016, USA) for environmental health

  • 👩‍👦 Healthy Communities Hero Award (2018) by Moms Across America

  • 🧬 Best Molecular Biology Academic (2023) by Healthcare and Pharmaceutical Awards

These recognitions celebrate both his scientific contributions and his enduring stand for public and planetary well-being.

🔮 LEGACY AND FUTURE CONTRIBUTIONS

Prof. Séralini’s legacy lies in his unyielding pursuit of truth and scientific responsibility. His work continues to influence environmental regulations, academic discussions on GMO transparency, and the ethics of scientific disclosure. By combining high-impact research with public education, he has shaped both policy and public understanding of environmental health. Looking ahead, he is expected to continue his research and advocacy, leaving a lasting imprint on science for society.

✍️ FINAL NOTE

Prof. Gilles-Éric Séralini embodies the role of the engaged scientist—one who not only contributes to molecular biology but also defends ethical, independent, and public-interest science. His career is a testament to the power of standing firm in the face of controversy for the greater good. Through research, teaching, and public outreach, he continues to champion a science that prioritizes human and ecological health above industrial interests.

 📚 TOP NOTES PUBLICATIONS

RETRACTED: Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize

    • Authors: GE Séralini, E Clair, R Mesnage, S Gress, N Defarge, M Malatesta, et al.

    • Journal: Food and Chemical Toxicology

    • Year: 2012

Differential effects of glyphosate and roundup on human placental cells and aromatase

    • Authors: S Richard, S Moslemi, H Sipahutar, N Benachour, GE Séralini

    • Journal: Environmental Health Perspectives

    • Year: 2005

Glyphosate-based herbicides are toxic and endocrine disruptors in human cell lines

    • Authors: C Gasnier, C Dumont, N Benachour, E Clair, MC Chagnon, GE Séralini

    • Journal: Toxicology

    • Year: 2009

Glyphosate formulations induce apoptosis and necrosis in human umbilical, embryonic, and placental cells

    • Authors: N Benachour, GE Séralini

    • Journal: Chemical Research in Toxicology

    • Year: 2009

Potential toxic effects of glyphosate and its commercial formulations below regulatory limits

    • Authors: R Mesnage, N Defarge, JS De Vendômois, GE Séralini

    • Journal: Food and Chemical Toxicology

    • Year: 2015

Ethoxylated adjuvants of glyphosate-based herbicides are active principles of human cell toxicity

    • Authors: R Mesnage, B Bernay, GE Séralini

    • Journal: Toxicology

    • Year: 2013